Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease

被引:14
|
作者
Cui, Jing [1 ]
Zhao, Panxiong [2 ]
Ren, Zhentai [3 ]
Liu, Baoping [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Nucl Med, Zhengzhou, Henan, Peoples R China
[2] Henan Univ, Affiliated Hosp 1, Dept Nucl Med, Kaifeng, Henan, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 5, Dept Radiat Oncol, Zhengzhou, Henan, Peoples R China
关键词
F-18-FDG PET; FDG-PET; CANCER; INDEX;
D O I
10.1097/MD.0000000000001356
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To assess the clinical value of dual time point imaging (DTPI) fluorine-18fludeoxyglucose (18F-FDG) positron emission tomography (PET)/CT in differentiating malignancy and benign disease of patients with focally increased gastric uptake.Patients who present focally increased 18F-FDG uptake in gastric wall on conventional PET/CT imaging received delayed imaging. PET/CT scans were acquired at 1 and 2hours (early and delayed imaging) after 18F-FDG injection. The maximum standardized uptake value (SUV) was calculated. The SUVmax of the early and delayed imaging acquisition were signed S1 and S2, respectively. The receiver operating characteristic curve (ROC) of the S1, S2, and the retention index (RI) were drawn to find the best cut-off point value for differential diagnosis. Sensitivity, specificity, Youden index, and the area under the curve (AUC) were calculated, respectively.From September 2010 to May 2015, 74 patients (56 male and 18 female; age of 5712 years; range, 32-86 years) referring for areas of focally increased uptake of 18F-FDG in gastric wall received delayed imaging. The S1 was 5.0 +/- 1.4 (range, 1.9-11.3), and S2 was 5.9 +/- 2.7 (range, 1.0-16.3). The SUVmax were increased in 52 patients in delayed imaging, with 85% (44/52 cases) appeared malignant; decreased in 20 patients, and 90% (18/20 cases) were benign; 2 patients of benign had not changed. The change of SUVmax between malignant and benign was significant difference (t=-5.785, P=0.000).Taking the S1, S2, and RI higher than 4.6%, 5.1%, and 13% as positive diagnostic criteria, the sensitivity were 65.2%,87.0%, and 87.0%, respectively; the specificity were 64.3%, 82.1%, and 89.3%; the Youden index were 0.332, 0.693, and 0.770; AUC were 0.635 (95% confidence intervals (95% CI) 0.507-0.764), 0.873 (95% CI, 0.786-0.961), and 0.923 (95% CI, 0.854-0.992).DTPI is more precise to distinct malignant from benign gastric diseases compared with conventional imaging, and it is readily accessible.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease
    Mavi, Ayse
    Basu, Sandip
    Cermik, Tevfik F.
    Urhan, Muammer
    Bathaii, Mehdi
    Thiruvenkatasamy, Dhurairaj
    Houseni, Mohamed
    Dadparvar, Simin
    Alavi, Abass
    MOLECULAR IMAGING AND BIOLOGY, 2009, 11 (05) : 369 - 378
  • [32] Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease
    Ayse Mavi
    Sandip Basu
    Tevfik F. Cermik
    Muammer Urhan
    Mehdi Bathaii
    Dhurairaj Thiruvenkatasamy
    Mohamed Houseni
    Simin Dadparvar
    Abass Alavi
    Molecular Imaging and Biology, 2009, 11 : 369 - 378
  • [33] The role of dual time point PET/CT for distinguishing malignant from benign focal 18F-FDG uptake duodenal lesions
    Sa, Ri
    Zhao, Hong-Guang
    Dai, Yu-Yin
    Guan, Feng
    MEDICINE, 2018, 97 (38)
  • [34] The role of 18F-FDG PET/CT in differentiating malignant from benign portal vein thrombosis
    Shengping Hu
    Jian Zhang
    Chao Cheng
    Qinghua Liu
    Gaofeng Sun
    Changjing Zuo
    Abdominal Imaging, 2014, 39 : 1221 - 1227
  • [35] Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions
    Michihiro Nakayama
    Atsutaka Okizaki
    Shunta Ishitoya
    Miki Sakaguchi
    Junichi Sato
    Tamio Aburano
    Annals of Nuclear Medicine, 2013, 27 : 163 - 169
  • [36] Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions
    Nakayama, Michihiro
    Okizaki, Atsutaka
    Ishitoya, Shunta
    Sakaguchi, Miki
    Sato, Junichi
    Aburano, Tamio
    ANNALS OF NUCLEAR MEDICINE, 2013, 27 (02) : 163 - 169
  • [37] The role of 18F-FDG PET/CT in differentiating malignant from benign portal vein thrombosis
    Hu, Shengping
    Zhang, Jian
    Cheng, Chao
    Liu, Qinghua
    Sun, Gaofeng
    Zuo, Changjing
    ABDOMINAL IMAGING, 2014, 39 (06): : 1221 - 1227
  • [38] Usefulness of 18F-FDG PET/CT for differentiating malignant from benign focal parotid lesions
    Park, Soo Bin
    Choi, Joon Young
    Lee, Eun Jeong
    Yoo, Jang
    Cheon, Miju
    Cho, Suk Kyong
    Choe, Yearn Seong
    Lee, Kyung-Han
    Kim, Byung-Tae
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [39] Comparison of 18F-FDG PET/CT imaging with different dual time 18F-FDG PET/CT with forced diuresis in clinical diagnosis of prostate cancer
    Yu, Longhua
    Huang, Shiming
    Wu, Siyu
    Yue, Jianlan
    Yin, Liang
    Lin, Zhichun
    MEDICINE, 2023, 102 (02) : E32331
  • [40] Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy
    Frank I. Lin
    Jyotsna E. Rao
    Erik S. Mittra
    Kavitha Nallapareddy
    Alka Chengapa
    David W. Dick
    Sanjiv Sam Gambhir
    Andrei Iagaru
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 262 - 270